Willem L.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Phase II Study of Ezabenlimab in PD-L1-Expressing Patients with Minimal Residual Disease Following Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
- Efficacy and Safety of REGN7508 for Primary Prophylaxis of Cancer-Associated Thrombosis in Patients with Solid Tumors Undergoing Cancer Treatment
Data & Insights
Has run more than one trial at 131 of 302 partner sites.
Specializations
Thoracic and Upper Aerodigestive Oncology
Medical oncology activity is strongly concentrated in advanced non-small cell lung cancer, small cell lung cancer, and pleural mesothelioma, with additional involvement in head and neck squamous cell carcinoma. The trial portfolio includes treatment settings spanning unresectable, metastatic, recurrent, and perioperative disease.
- NSCLC
- SCLC
- Head and neck squamous cell carcinoma
- Pleural mesothelioma
Therapeutic interest extends to immunotherapy, targeted therapy, and combination regimens used in lung and head and neck malignancies.
Breast, Gynecologic, and Melanoma Malignancies
The investigator is active in solid-tumor research across breast cancer, ovarian cancer, endometrial cancer, prostate cancer, and melanoma, including both early-stage and advanced disease. This area includes hormone receptor–driven tumors, high-risk recurrence settings, and metastatic disease.
- Breast cancer
- Ovarian cancer
- Endometrial cancer
- Melanoma
Research activity reflects interest in endocrine therapy, antibody-drug conjugates, and immune checkpoint inhibitors for women’s cancers and skin cancer.
Gastroenterology and Inflammatory Bowel Disease
Clinical trial involvement includes Crohn's disease, ulcerative colitis, and broader inflammatory bowel disease, with attention to active disease, postoperative recurrence, and maintenance treatment. The portfolio also includes associated immune-mediated gastrointestinal conditions.
- Crohn's disease
- Ulcerative colitis
- Inflammatory bowel disease
- Postoperative recurrence
Therapeutic focus includes biologic therapy, immune modulation, and strategies aimed at sustained intestinal disease control.
Urologic and Genitourinary Oncology
The investigator is involved in studies of non-muscle-invasive bladder cancer, urothelial carcinoma, and prostate cancer, covering both localized and advanced settings. This research area also includes biomarker-informed treatment selection in genitourinary malignancies.
- Non-muscle-invasive bladder cancer
- Urothelial carcinoma
- Prostate cancer
- Biomarker-guided therapy
Areas of interest include intravesical therapy, systemic anticancer therapy, and treatment approaches for recurrent or high-risk disease.
Cardiometabolic and Hematologic Conditions
Beyond oncology, the trial landscape includes coronary artery disease, atrial fibrillation, stroke prevention, heart failure, type 2 diabetes, and obesity, alongside hematologic malignancies such as lymphoma, chronic lymphocytic leukemia, and multiple myeloma. This breadth indicates engagement with both cardiovascular risk reduction and blood cancer treatment.
- Coronary artery disease
- Stroke prevention
- Heart failure
- Lymphoma and multiple myeloma
Therapeutic interests include antithrombotic therapy, metabolic disease management, and modern approaches to hematologic oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.